Addex TherapeuticsADXN
Market Cap: $12M
About: Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.
Employees: 23
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
295% more capital invested
Capital invested by funds: $4.99K [Q1] → $19.7K (+$14.7K) [Q2]
100% more funds holding
Funds holding: 1 [Q1] → 2 (+1) [Q2]
0% more ownership
Funds ownership: 0% [Q1] → 0% (+0%) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 121 / 288 met price target | 168%upside $30 | Buy Reiterated | 28 Aug 2024 |
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 121 / 288 met price target | 168%upside $30 | Buy Upgraded | 31 Jul 2024 |
Financial journalist opinion
Based on 6 articles about ADXN published over the past 30 days